SUMMARY
The research of Megan M. Dulohery Scrodin, M.D., focuses on chronic obstructive pulmonary disease (COPD), alpha-1 antitrypsin deficiency and asthma. Dr. Dulohery Scrodin also leads in practice innovation.
In partnership with AstraZeneca, Dr. Dulohery Scrodin has recruited patients to the Oberon and Prospero studies. These studies are exploring tozorakimab, a novel agent to reduce COPD exacerbations. She also has partnered with Galvanize Therapeutics Inc. to recruit patients to the RheOx study. This study focuses on a new minimally invasive bronchoscopy therapy that uses pulsed electric field energy. The energy induces nonthermal ablation to mucus-producing cells in the airway, thereby improving symptom control in patients with COPD and chronic bronchitis.
Dr. Dulohery Scrodin is exploring new research for remote patient monitoring and artificial intelligence to predict COPD exacerbations and complications.
Focus areas
- COPD.
- Alpha-1 antitrypsin deficiency.
- Asthma.
- Practice innovation.
- Remote patient monitoring.
- Artificial intelligence.
Significance to patient care
Dr. Dulohery Scrodin aims to have research studies available for patients with chronic airway disease, including COPD, asthma and alpha-1 antitrypsin deficiency. These patients need new treatments to better control symptoms, reduce healthcare use and improve quality of life.
While there have been amazing advancements in the treatment of airway disease, the work is not done. Each patient who comes to Mayo Clinic deserves the best, proven care and a chance to take part in research that may make care better for all.
Professional highlights
- Vice chair of outpatient practice, Department of Internal Medicine, Mayo Clinic, 2021-present.
- Practice chair, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 2020-present.
- Kern Health Care Delivery Scholar, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 2013-2014.